Corporate Banner
Satellite Banner
Scientific Community
Become a Member | Sign in
Home>News>This Article

OGT Announces the Release of New Genefficiency™ RNA Sequencing Service

Published: Thursday, October 04, 2012
Last Updated: Thursday, October 04, 2012
Bookmark and Share
Turning data into discovery for insightful gene expression analysis.

Oxford Gene Technology (OGT) has announced the release of its new Genefficiency™ RNA Sequencing (RNA-Seq) Service.

Taking advantage of OGT’s experience in optimized sequencing project design and advanced data analysis, this new service overcomes the need for expensive and time-intensive in-house bioinformatics analysis, and has a wide range of other benefits.

To ensure that researchers obtain informative data, OGT provides expert assistance throughout the duration of the project, from the initial stages of experimental design all the way through to the final results.

In addition, the results are presented in an easy-to-use, interactive report that makes the final expression analysis as fast and straightforward as possible.

By taking care of the complexity of sample and data processing, the new service makes RNA-Seq a widely accessible tool for revealing the complexities of the transcriptome.

RNA-Seq allows much broader discoveries at the transcriptome level than many other approaches. It provides the experimental freedom to identify unknown genes and isoforms without having to wait for new versions of exon or custom arrays and genome annotation updates.

Analysis of the data generated allows new information to be revealed, such as changes in transcript activity and variant analysis.

Additional analysis can reveal more in-depth knowledge on alternative splice junctions, allele specific expression and the identification of fusion proteins.

OGT’s Chief Executive Officer, Dr Mike Evans, commented: “Whilst RNA-Seq is a powerful and flexible technology, considerable challenges are presented in terms of the data analysis process. Our optimized pipeline has been specifically designed to help researchers quickly and easily overcome these obstacles, while our purpose-built interactive reporting tool delivers meaningful, accurate publication-ready results for researchers”.

OGT’s intuitive reporting tool allows the quick and effective interrogation of data. The results can be quickly and efficiently examined against a number of parameters, such as differentially expressed genes.

Furthermore, researchers can instantly investigate distinct isoforms for specified genes in order to determine those that are significantly contributing to differential expression at the individual gene-level.

As a comprehensive and fully integrated service, advice and consultation is provided as standard throughout the whole process.

The initial experimental design is fully customizable in order to meet study objectives, with OGT advising on aspects such as the correct combination of starting material and sequencing depth.

Rigorous quality control metrics are used to confirm that reliable, parsimonious, well-mapped reads are informing downstream analysis.

Once the data report is received, a complimentary consultation with an OGT bioinformatician allows the researcher to maximize the potential power of the reporting tool.

In this way, the depth of value provided by the new Genefficiency™ RNA-Seq Service ensures that researchers will quickly generate biological insight from their gene expression research project.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Oxford Gene Technology Expands Leadership in Genomic Medicine
The Company today announced the acquisition of Cambridge-based Cytocell Limited.
Tuesday, March 04, 2014
OGT Strengthens Focus on Cancer Biomarkers
Oxford Gene Technology announce the appointment of Dr Bob Holland as Chief Medical Officer.
Monday, October 21, 2013
OGT Appoints Dr Bob Holland as CMO
Company strengthens focus on cancer biomarkers.
Monday, October 21, 2013
OGT Awarded Best Medtech Dealmaker by Oxford Bioscience Network
Award recognizes OGT’s collaboration with Birmingham and Salisbury NHS Regional Genetics Laboratories.
Wednesday, October 09, 2013
Exploring the Next Generation of Cancer Genomics at BSGM
aCGH to NGS: OGT invites University of Oxford Professor to present latest research.
Thursday, September 12, 2013
OGT Forms Scientific Advisory Board
Peter Rigby appointed as SAB Chairman.
Wednesday, September 12, 2012
Oversubscribed OGT Workshop at ESHG 2012 Now Available Online
Experts discuss the use of arrays and NGS to identify causative mutations in cancer.
Thursday, July 19, 2012
OGT Signs Licensing Deal for Colorectal Cancer Biomarkers
OGT has entered into an exclusive licensing agreement with Inven2.
Thursday, February 23, 2012
Oxford Gene Technology and Abcodia Form Partnership
Companies combine expertise to advance biomarkers for the early diagnosis of pancreatic cancer.
Tuesday, November 08, 2011
OGT’s miRNA Profiling Service Provides Answers for Disease Research
Company has designed the microRNA profiling service designed to help researchers accelerate their discoveries.
Friday, May 16, 2008
Scientific News
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Exploring the Causes of Cancer
Queen's research to understand the regulation of a cell surface protein involved in cancer.
Nanocarriers May Carry New Hope for Brain Cancer Therapy
Berkeley lab researchers develop nanoparticles that can carry therapeutics across the brain blood barrier.
RNA-Based Drugs Give More Control Over Gene Editing
CRISPR/Cas9 gene editing technique can be transiently activated and inactivated using RNA-based drugs, giving researchers more precise control in correcting and inactivating genes.
University of Glasgow Researchers Make An Impact in 60 Seconds
Early-career researchers were invited to submit an engaging, dynamic and compelling 60 second video illuminating an aspect of their research.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
Dead Bacteria to Kill Colorectal Cancer
Scientists from Nanyang Technological University (NTU Singapore) have successfully used dead bacteria to kill colorectal cancer cells.
CRISPR-Cas9 Gene Editing: Check Three Times, Cut Once
Two new studies from UC Berkeley should give scientists who use CRISPR-Cas9 for genome engineering greater confidence that they won’t inadvertently edit the wrong DNA.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos